The production of amyloid-β can be reduced by “…inhibitors of β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1.” Therefore, BACE1 inhibitors would seem to offer promising drug therapies for AZ (and perhaps for CAA?). Although nearly all trials have been unsuccessful and discontinued, any harmful effects are reversible. It therefore seems that treatments with lower levels of BACE1 might be successful. https://www.nature.com/articles/s41582-021-00545-1